(Q24244817)

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Frontal-subcortical circuits and human behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Donepezil for vascular cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Absence of cholinergic deficits in "pure" vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Clinical features of MRI-defined subcortical vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Bedside assessment of executive cognitive impairment: the executive interview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

The Association between White Matter Lesions on Magnetic Resonance Imaging and Noncognitive Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004746.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD004746.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

3711772

3711772

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference